^
Association details:
| Biomarker: | Chr t(11;14) |
|---|---|
| Cancer: | Multiple Myeloma |
| Regimen: | TD (dexamethasone injection + thalidomide) |
| Direction: | Resistant |
Evidence:
Source:
Title:
IMPACT OF T(11;14) ACCORDING TO INDUCTION REGIMEN IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS: LONG TERM FOLLOW-UP OF GEM05MENOS65 PETHEMA/GEM STUDY
Published date:
05/12/2021
Excerpt:
A total of 53 (16%) patients were positive for t(11;14)...shorter PFS was observed in patients with t(11;14) in the TD (30 vs. 46 months; p=0.03) and VTD arms (28 vs. 72 months; p=0.003)...bortezomib and thalidomide-based induction regimens (VTD/TD) are suboptimal in patients with t(11;14) concerning response rates and PFS...
Trial ID:
